Reason for comment York Pharma has just announced the acquisition of CellTran, a-Sheffield based company specialised in cellular based wound care and burn dermal therapy. CellTran had been funded to the tune of around £11 million by, amongst others the Wellcome Trust and local Development Authority money. York purchased the assets of the company from its administrators for £70,000. The company is located in the same building as York's Sheffield base and has developed two cellular therapy products (Myskin (TM) and Cryoskin (TM)) that have been launched and are manufactured in a facility that is licensed by the HTA (Human Tissue Authority).

Myskin is a cultured, autologous (from the patient) silicon-based epidermal substitute that is used for the treatment of various intractable or difficult to treat wounds (diabetic foot ulcers and other non-healing wounds) as well as partial thickness burns. Cryoskin is a monolayered allogeneic

...